Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy

Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response. After 6 weeks of pegylated interferon-alpha2a/ribavirin therapy, 74 chronic hepatitis C patients were ra...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2008-06, Vol.48 (6), p.932-938
Main Authors: Pugnale, Paolo, Herrmann, Eva, Neumann, Avidan U, Pawlotsky, Jean-Michel, Schalm, Solko W, Ferrari, Carlo, Homburger, Yonit, Zeuzem, Stefan, Negro, Francesco
Format: Article
Language:English
Subjects:
Adult
Aged
Antiviral Agents - therapeutic use
Drug Therapy, Combination
Female
Hepacivirus - drug effects
Hepacivirus - physiology
Hepatitis C - blood
Hepatitis C - drug therapy
Hepatitis C - physiopathology
Humans
Interferon-alpha - therapeutic use
Leukocytes, Mononuclear - virology
Male
Middle Aged
Plasma - virology
Recombinant Proteins
Ribavirin - therapeutic use
RNA, Viral - blood
Viral Load
Virus Replication - drug effects
Virus Replication - physiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response. After 6 weeks of pegylated interferon-alpha2a/ribavirin therapy, 74 chronic hepatitis C patients were randomized to individualized or standard treatments for another 42 weeks. HCV RNA was quantified in peripheral blood mononuclear cells (PBMCs) by TaqMan-based real-time PCR and compared to plasma HCV RNA. HCV RNA declines in PBMCs and plasma were comparable during the initial 12 weeks of therapy (Spearman's rank correlation range over different time points, 0.73-0.97). However, a delay of HCV RNA decay in PBMCs, expected if kinetics in PBMCs only reflected kinetics in plasma, was rarely observed. For many patients, HCV RNA decline in PBMCs started as early as in plasma and for some of them the kinetics strongly differed in the two compartments, hinting at a compartment-specific HCV replication and treatment effect. Fast viral decay in PBMCs was associated with sustained virological response, but viral kinetics in PBMCs added only minor predictive information compared with kinetics in plasma. Future kinetics studies of HCV RNA during therapy with new antivirals should take into account their compartment-specific effect.
ISSN:0168-8278
DOI:10.1016/j.jhep.2008.02.018